Diabetic gastroenteropathy: modern methods of diagnosis and treatment

Diabetes mellitus is a chronic disease with a growing prevalence worldwide, however, the prevalence of its complications, including gastroenteropathy, is also increasing. The pathophysiology of diabetic gastroenteropathy (DH) combines hyperglycemia, vagus nerve dysfunction, decreased expression of nitric oxide synthase in the myenteric plexus, changes in the interstitial Cajal cell network, as well as oxidative stress. Clinical signs of DH are gastroesophageal reflux, gastroparesis, constipation, abdominal pain and diarrhea. Among the diagnostic methods are manometry with pH measurement (assessment of esophageal motility), gastric emptying scintigraphy, respiratory test (to assess gastroparesis), aspiration and cultivation of the contents of the jejunum (to diagnose bacterial overgrowth syndrome). To date, there is no definitive treatment for DH — an interdisciplinary approach is aimed at slowing the progression of the disease, relieving symptoms and restoring gastrointestinal function. Patients are recommended a diet low in simple sugars and high in fiber; optimization of glycemic control with a target glycemia of less than 180 mg/dl. As for drug therapy, the use of prokinetics and antiemetics is justified, and in case of excessive bacterial growth syndrome, antibacterial therapy (rifaximin) is carried out. Modern approaches to the treatment of DH are also accumulating, including the use of botulinum toxin, pyloroplasty and electrical stimulation of the stomach in individual patients. Despite the constant development of new treatments, they are not yet able to completely cure DH in the near future, which makes it necessary to conduct further research in this area.

1. Kumar M, Chapman A, Javed S, et al. The Investigation and Treatment of Diabetic Gastroparesis. Clin Ther. 2018;40(6):850-861. doi: https://doi.org/10.1016/j.clinthera.2018.04.012

2. Borgoño CA, Zinman B. Insulins: past, present, and future. Endocrinol Metab Clin North Am. 2012;41(1):1-24. doi: https://doi.org/10.1016/j.ecl.2012.03.002

3. Quianzon CC, Cheikh I. History of insulin. J Community Hosp Intern Med Perspect. 2012;2(2):18701. doi: https://doi.org/10.3402/jchimp.v2i2.18701

4. Dedov II, Shestakova MV, Vikulova OK, et al. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021;24(3):204-221. (In Russ.). doi: https://doi.org/10.14341/DM12759

5. Jung HK, Choung RS, Locke GR 3rd, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136(4):1225-1233. doi: https://doi.org/10.1053/j.gastro.2008.12.047

6. Jung HK, Choung RS, Locke GR 3rd, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136(4):1225-1233. doi: https://doi.org/10.1053/j.gastro.2008.12.047

7. Koch KL, Calles-Escandón J. Diabetic gastroparesis. Gastroenterol Clin North Am. 2015;44(1):39-57. doi: https://doi.org/10.1016/j.gtc.2014.11.005

8. Kurniawan AH, Suwandi BH, Kholili U. Diabetic Gastroenteropathy: A Complication of Diabetes Mellitus. Acta Med Indones. 2019;51(3):263-271

9. Goyal RK, Guo Y, Mashimo H. Advances in the physiology of gastric emptying. Neurogastroenterol Motil. 2019;31(4):e13546. doi: https://doi.org/10.1111/nmo.13546

10. Sullivan A, Temperley L, Ruban A. Pathophysiology, Aetiology and Treatment of Gastroparesis. Dig Dis Sci. 2020;65(6):1615-1631. doi: https://doi.org/10.1007/s10620-020-06287-2

11. Kuo P, Rayner CK, Jones KL, Horowitz M. Pathophysiology and management of diabetic gastropathy: a guide for endocrinologists. Drugs. 2007;67(12):1671-1687. doi: https://doi.org/10.2165/00003495-200767120-00003

12. Schvarcz E, Palmér M, Aman J, et al. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology. 1997;113(1):60-66. doi: https://doi.org/10.1016/s0016-5085(97)70080-5

13. Watkins CC, Sawa A, Jaffrey S, et al. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest. 2000;106(3):373-384. doi: https://doi.org/10.1172/JCI8273

14. Stevens JE, Jones KL, Rayner CK, Horowitz M. Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives. Expert Opin Pharmacother. 2013;14(9):1171-1186. doi: https://doi.org/10.1517/14656566.2013.795948

15. Vanormelingen C, Tack J, Andrews CN. Diabetic gastroparesis. Br Med Bull. 2013;105(1):213-230. doi: https://doi.org/10.1093/bmb/ldt003

16. Leites Iu.G., Galstian G.R., Marchenko E. V. Gastroenterologicheskie oslozhneniia sakharnogo diabeta. Consilium Medicum. 2007;2:25-32. (In Russ.).

17. Meldgaard T, Keller J, Olesen AE, et al. Pathophysiology and management of diabetic gastroenteropathy. Therap Adv Gastroenterol. 2019;12(1):175628481985204. doi: https://doi.org/10.1177/1756284819852047

18. Nguyen LA, Snape WJ Jr. Clinical presentation and pathophysiology of gastroparesis. Gastroenterol Clin North Am. 2015;44(1):21-30. doi: https://doi.org/10.1016/j.gtc.2014.11.003

19. Gangula PR, Maner WL, Micci MA, et al. Diabetes induces sex-dependent changes in neuronal nitric oxide synthase dimerization and function in the rat gastric antrum. Am J Physiol Gastrointest Liver Physiol. 2007;292(3):725-733. doi: https://doi.org/10.1152/ajpgi.00406.2006

20. Grover M, Bernard CE, Pasricha PJ, et al. NIDDK Gastroparesis Clinical Research Consortium (GpCRC). Clinical-histological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. Neurogastroenterol Motil. 2012;24(6):531-539. doi: https://doi.org/10.1111/j.1365-2982.2012.01894.x

21. Du YT, Rayner CK, Jones KL, et al. Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management. Diabetes Care. 2018;41(3):627-637. doi: https://doi.org/10.2337/dc17-1536

22. Chedid V, Brandler J, Vijayvargiya P, et al. Characterization of Upper Gastrointestinal Symptoms, Gastric Motor Functions, and Associations in Patients with Diabetes at a Referral Center. Am J Gastroenterol. 2019;114(1):143-154. doi: https://doi.org/10.1038/s41395-018-0234-1

23. Iyer PG, Borah BJ, Heien HC, et al. Association of Barrett’s esophagus with type II Diabetes Mellitus: results from a large population-based case-control study. Clin Gastroenterol Hepatol. 2013;11(9):1108-1114. doi: https://doi.org/10.1016/j.cgh.2013.03.024

24. George NS, Rangan V, Geng Z, et al. Distribution of Esophageal Motor Disorders in Diabetic Patients With Dysphagia. J Clin Gastroenterol. 2017;51(10):890-895. doi: https://doi.org/10.1097/MCG.0000000000000894

25. Concepción Zavaleta MJ, Gonzáles Yovera JG, Moreno Marreros DM, et al. Diabetic gastroenteropathy: An underdiagnosed complication. World J Diabetes. 2021;12(6):794-809. doi: https://doi.org/10.4239/wjd.v12.i6.794

26. Meldgaard T, Olesen SS, Farmer AD, et al. Diabetic Enteropathy: From Molecule to Mechanism-Based Treatment. J Diabetes Res. 2018;2018(6):1-12. doi: https://doi.org/10.1155/2018/3827301

27. Vijayvargiya P, Jameie-Oskooei S, Camilleri M, et al. Association between delayed gastric emptying and upper gastrointestinal symptoms: a systematic review and meta-analysis. Gut. 2019;68(5):804-813. doi: https://doi.org/10.1136/gutjnl-2018-316405

28. Aleppo G, Calhoun P, Foster NC, et al. T1D Exchange Clinic Network. Reported gastroparesis in adults with type 1 diabetes (T1D) from the T1D Exchange clinic registry. J Diabetes Complications. 2017;31(12):1669-1673. doi: https://doi.org/10.1016/j.jdiacomp.2017.08.014

29. Sommers T, Mitsuhashi S, Singh P, et al. Prevalence of Chronic Constipation and Chronic Diarrhea in Diabetic Individuals in the United States. Am J Gastroenterol. 2019;114(1):135-142. doi: https://doi.org/10.1038/s41395-018-0418-8

30. Choung RS, Locke GR 3rd, Schleck CD, et al. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol. 2012;107(1):82-88. doi: https://doi.org/10.1038/ajg.2011.310

31. Mouli VP, Ahuja V. Questionnaire based gastroesophageal reflux disease (GERD) assessment scales. Indian J Gastroenterol. 2011;30(3):108-117. doi: https://doi.org/10.1007/s12664-011-0105-9

32. Revicki DA, Camilleri M, Kuo B, et al. Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD). Neurogastroenterol Motil. 2012;24(5):456-463. doi: https://doi.org/10.1111/j.1365-2982.2012.01879.x

33. Neri L, Conway PM, Basilisco G. Laxative Inadequate Relief Survey (LIRS) Group. Confirmatory factor analysis of the Patient Assessment of Constipation-Symptoms (PAC-SYM) among patients with chronic constipation. Qual Life Res. 2015;24(7):1597-1605. doi: https://doi.org/10.1007/s11136-014-0886-2

34. Alipour Z, Khatib F, Tabib SM, et al. Assessment of the Prevalence of Diabetic Gastroparesis and Validation of Gastric Emptying Scintigraphy for Diagnosis. Mol Imaging Radionucl Ther. 2017;26(1):17-23. doi: https://doi.org/10.4274/mirt.61587

35. Farrell MB. Gastric Emptying Scintigraphy. J Nucl Med Technol. 2019;47(2):111-119. doi: https://doi.org/10.2967/jnmt.117.227892

36. Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med. 2007;356(8):820-829. doi: https://doi.org/10.1056/NEJMcp062614

37. Farmer AD, Pedersen AG, Brock B, et al. Type 1 diabetic patients with peripheral neuropathy have pan-enteric prolongation of gastrointestinal transit times and an altered caecal pH profile. Diabetologia. 2017;60(4):709-718. doi: https://doi.org/10.1007/s00125-016-4199-6.

38. Asha MZ, Khalil SFH. Pharmacological Approaches to Diabetic Gastroparesis: A systematic review of randomised clinical trials. Sultan Qaboos Univ Med J. 2019;19(4):291-304. doi: https://doi.org/10.18295/SQUMJ.2019.19.04.004

39. Careyva B, Stello B. Diabetes Mellitus: Management of Gastrointestinal Complications. Am Fam Physician. 2016;94(12):980-986.

40. Kedar A, Nikitina Y, Henry OR, et al. Gastric dysmotility and low serum vitamin D levels in patients with gastroparesis. Horm Metab Res. 2013;45(1):47-53. doi: https://doi.org/10.1055/s-0032–1323689

41. Ajumobi AB, Griffin RA. Diabetic gastroparesis: evaluation and management. Hosp Physician. 2008;44:27-35.

42. Olausson EA, Störsrud S, Grundin H, et al. A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial. Am J Gastroenterol. 2014;109(3):375-385. doi: https://doi.org/10.1038/ajg.2013.453

43. Jalleh R, Marathe CS, Rayner CK, et al. Diabetic Gastroparesis and Glycaemic Control. Curr Diab Rep. 2019;19(12):153. doi: https://doi.org/10.1007/s11892–019-1281-8

44. Parkman HP, Yates KP, Hasler WL, et al. NIDDK Gastroparesis Clinical Research Consortium. Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis. Gastroenterology. 2011;141(2):486-498. doi: https://doi.org/10.1053/j.gastro.2011.04.045

45. Farmer AD, Kadirkamanathan SS, Aziz Q. 3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43(S1):S32-S36. doi: https://doi.org/10.2337/dc20-S003

46. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2–drug combinations. Ann Intern Med. 2011;154(9):602-613. doi: https://doi.org/10.7326/0003-4819-154-9-201105030-00336

47. Sharma D, Morrison G, Joseph F, et al. The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis. Diabetologia. 2011;54(11):2768-2770. doi: https://doi.org/10.1007/s00125-011-2282–6

48. Patterson D, Abell T, Rothstein R, et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol. 1999;94(5):1230-1234. doi: https://doi.org/10.1111/j.1572–0241.1999.00456.x

49. Lacy BE, Crowell MD, Schettler-Duncan A, et al. The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus. Diabetes Care. 2004;27(10):2341-2347. doi: https://doi.org/10.2337/diacare.27.10.2341

50. Mekaroonkamol P, Li LY, Dacha S, et al. Gastric peroral endoscopic pyloromyotomy (G-POEM) as a salvage therapy for refractory gastroparesis: a case series of different subtypes. Neurogastroenterol Motil. 2016;28(8):1272-1277. doi: https://doi.org/10.1111/nmo.12854

51. Abell T, McCallum R, Hocking M, et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology. 2003;125(2):421-428. doi: https://doi.org/10.1016/s0016-5085(03)00878-3

52. Abell TL, Johnson WD, Kedar A, et al. A double-masked, randomized, placebo-controlled trial of temporary endoscopic mucosal gastric electrical stimulation for gastroparesis. Gastrointest Endosc. 2011;74(3):496-503. doi: https://doi.org/10.1016/j.gie.2011.05.022

53. Lysy J, Israeli E, Goldin E. The prevalence of chronic diarrhea among diabetic patients. Am J Gastroenterol. 1999;94(8):2165-2170. doi: https://doi.org/10.1111/j.1572–0241.1999.01289.x

54. Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009;18(3):349-358. doi: https://doi.org/10.1517/13543780902780175

55. Ebert EC. Gastrointestinal complications of diabetes mellitus. Dis Mon. 2005;51(12):620-663. doi: https://doi.org/10.1016/j.disamonth.2005.11.002

56. Noureddin S, Mohsen J, Payman A. Effects of psyllium vs. placebo on constipation, weight, glycemia, and lipids: A randomized trial in patients with type 2 diabetes and chronic constipation. Complement Ther Med. 2018;40(S1):1-7. doi: https://doi.org/10.1016/j.ctim.2018.07.004

57. Soltanian N, Janghorbani M. A randomized trial of the effects of flaxseed to manage constipation, weight, glycemia, and lipids in constipated patients with type 2 diabetes. Nutr Metab (Lond). 2018;15(1):36. doi: https://doi.org/10.1186/s12986-018-0273-z

58. Christie J, Shroff S, Shahnavaz N, et al. A Randomized, Double-Blind, Placebo-Controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients. Am J Gastroenterol. 2017;112(2):356-364. doi: https://doi.org/10.1038/ajg.2016.531

59. Haas S, Brock C, Krogh K, et al. Does Sacral Nerve Stimulation Improve Continence Through Enhanced Sensitivity of the Anal Canal? A Pilot Study. Dis Colon Rectum. 2016;59(11):1039-1046. doi: https://doi.org/10.1097/DCR.0000000000000677